Log In
Print
BCIQ
Print
Print this Print this
 

firategrast (SB-683699) (formerly T-0047)

Also known as: 683699

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionDual integrin alpha(4) antagonist
Molecular Target Integrin alpha(4) (VLA-4 ) (CD49D)
Mechanism of ActionBinds integrin alpha(4)
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation

Partner

Mitsubishi Tanabe Pharma Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today